Sign in
Taking people in United StatesPhase 1/2

Vaccine against cytomegalovirus in children having a donor stem cell transplant

Tests a cytomegalovirus vaccine in children receiving donor stem cell transplants.

Key facts

Who runs it
City of Hope Medical Center
Where
Duarte, United StatesSee the site
Trial code
Registry title
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
Status
Recruiting
Phase
Phase 1/2
People taking part
80 people, planned
Started
31 Aug 2018
Expected to end
11 Dec 2026
Type of study
Interventional
Treatments tested
  • Laboratory Biomarker Analysis
  • Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people who carry CMV (cytomegalovirus) and are planned to get a stem cell transplant from a donor. It tests a CMV vaccine given after the transplant.

Age
1 Year to 21 Years
Sex
All sexes can join
Disease stage
A planned donor (allogeneic) stem cell transplant. The donor's tissue type must be 9/10 or 10/10 compatible, with no T-cell removal from the graft. In phase I only, a related half-compatible (3/6) donor is also allowed.
Earlier treatment
No earlier test CMV vaccine. No anti-CMV therapy in the last 6 months. Pre-transplant ATG is allowed.
Biomarker or test result
CMV antibody test positive at the time of transplant. HIV and hepatitis C antibody tests negative. If hepatitis B core antibody is positive, no HBV DNA within 2 months of registration.

Main reasons for not taking part

  • Cord blood transplant
  • Inborn (congenital) immune deficiency
  • Active autoimmune disease needing whole-body immune-suppressing drugs in the last 5 years, except aplastic anemia
  • Pregnant or breastfeeding
  • Use of drugs that act against CMV, such as ganciclovir, or T-cell depleting drugs such as alemtuzumab

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • All subjects (or their guardians) must have the ability to understand and the willingness to sign a written informed consent; age appropriate assent will be obtained per institutional guidelines; to allow non-English patients to participate in this study, bilingual health services will be provided in the appropriate language when feasible
  • Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
  • Planned allogenic (allo)-HCT, with 9/10 or 10/10 (A, B, C, DRB1, DQB1) high/intermediate resolution HLA donor allele matching and with no T-cell depletion of graft
  • Planned related HCT with molecular 3/6 HLA donor allele matching (haploidentical) (for phase I only)
  • CMV seropositive at the time of HCT
  • Conditioning and immunosuppressive regimens according to institutional guidelines are permitted
  • Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
  • Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV); if hepatitis B virus (HBV) core seropositive, absence of HBV deoxyribonucleic acid (DNA) within 2 months of registration
  • Agreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to 90 days post-HCT; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately

Who cannot take part

  • TRANSPLANT RELATED CRITERIA: Patients undergoing cord blood transplant (CB-HCT)
  • Any prior investigational CMV vaccine
  • Anti-CMV therapy in the last 6 months
  • Live attenuated vaccines
  • Allergy treatment with antigens injections
  • Alemtuzumab, cyclophosphamide, ATG or any equivalent in vivo T-cell depleting agent; Note: Pre-transplant ATG is permitted
  • Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valine (VAL), FOS, Cidofovir, CMX-001, maribavir; acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV)
  • Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment; intravenous immunoglobulin therapy (IVIG) is allowed
  • Other investigational product-concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited
  • Other medications that might interfere with the evaluation of the investigational product
  • Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible, the exception to this is patients with aplastic anemia, who are eligible
  • Pregnant women and women who are lactating; CMV-MVA Triplex risks to pregnant women are unknown; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the administered vaccine, also breastfeeding should be discontinued if the mother is enrolled on this study
  • Medically indicated subunit (Engerix-B for HBV; Gardasil for human papillomavirus [HPV]) or killed vaccine (e.g. influenza, pneumococcal)
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/psychological issues, etc
  • Patients with congenital immune deficiency
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issue related to feasibility/logistics)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 21 years old?

Where in United States

  • City of Hope Medical CenterDuarte, United StatesContact: Anna B. PawlowskaTaking people

About the trial

What the trial wants to find out

This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vaccinia ankara vaccine may help people resist CMV life-threatening complications.

The group in the trial

  • Supportive Care (multi-antigen CMV-modified vaccinia ankara)Treatment being tested

    Patients receive multi-antigen CMV-modified vaccinia ankara vaccine IM on days 28 and 56 post-HCT.

    Treatment: Laboratory Biomarker Analysis and Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1/2 Clinical Study to Evaluate the Optimal Dose and the Protective Effect of CMV-MVA Triplex Vaccine in Pediatric Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant
Plain-language title
Vaccine against cytomegalovirus in children having a donor stem cell transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT03354728, who can take part
Record updated
20 October 2026